Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
55 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Sjogren's Syndrome - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Sjogren's Syndrome - Pipeline Review, H2 2014', provides an overview of the Sjogren's Syndrome's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Sjogren's Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sjogren's Syndrome and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Sjogren's Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Sjogren's Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Sjogren's Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Sjogren's Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Sjogren's Syndrome - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Sjogren's Syndrome pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Sjogren's Syndrome Overview 7 Therapeutics Development 8 Pipeline Products for Sjogren's Syndrome - Overview 8 Pipeline Products for Sjogren's Syndrome - Comparative Analysis 9 Sjogren's Syndrome - Therapeutics under Development by Companies 10 Sjogren's Syndrome - Therapeutics under Investigation by Universities/Institutes 11 Sjogren's Syndrome - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Sjogren's Syndrome - Products under Development by Companies 15 Sjogren's Syndrome - Products under Investigation by Universities/Institutes 16 Sjogren's Syndrome - Companies Involved in Therapeutics Development 17 Bristol-Myers Squibb Company 17 MedImmune, LLC 18 Novartis AG 19 Takeda Pharmaceutical Company Limited 20 Toleranzia AB 21 Sjogren's Syndrome - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 abatacept (recombinant) - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 ABS-11 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Cell Therapy for Type 1 Diabetes and Sjogrens Syndrome - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 CFZ-533 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 IMSO-001 - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 MEDI-4920 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 MLN-3126 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 NS2 - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Recombinant Protein for Sjogren's Syndrome - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Recombinant Protein to Antagonize LTB4 and C5 for Respiratory, Immunological, CNS and Hematological Disorders - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 VAY-736 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Sjogren's Syndrome - Recent Pipeline Updates 46 Sjogren's Syndrome - Dormant Projects 50 Sjogren's Syndrome - Discontinued Products 51 Sjogren's Syndrome - Product Development Milestones 52 Featured News & Press Releases 52 Dec 16, 2014: Aldeyra Therapeutics Abstract Accepted at 2015 American Academy of Allergy Asthma & Immunology Annual Meeting 52 Apr 22, 2011: Breakthrough study links Type 1 diabetes and Sjogren's syndrome 52 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 55 Disclaimer 55
List of Tables Number of Products under Development for Sjogren's Syndrome, H2 2014 8 Number of Products under Development for Sjogren's Syndrome - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 10 umber of Products under Investigation by Universities/Institutes, H2 2014 11 Comparative Analysis by Late Stage Development, H2 2014 12 Comparative Analysis by Clinical Stage Development, H2 2014 13 Comparative Analysis by Early Stage Development, H2 2014 14 Products under Development by Companies, H2 2014 15 Products under Investigation by Universities/Institutes, H2 2014 16 Sjogren's Syndrome - Pipeline by Bristol-Myers Squibb Company, H2 2014 17 Sjogren's Syndrome - Pipeline by MedImmune, LLC, H2 2014 18 Sjogren's Syndrome - Pipeline by Novartis AG, H2 2014 19 Sjogren's Syndrome - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 20 Sjogren's Syndrome - Pipeline by Toleranzia AB, H2 2014 21 Assessment by Monotherapy Products, H2 2014 22 Number of Products by Stage and Target, H2 2014 24 Number of Products by Stage and Mechanism of Action, H2 2014 26 Number of Products by Stage and Route of Administration, H2 2014 28 Number of Products by Stage and Molecule Type, H2 2014 30 Sjogren's Syndrome Therapeutics - Recent Pipeline Updates, H2 2014 46 Sjogren's Syndrome - Dormant Projects, H2 2014 50 Sjogren's Syndrome - Discontinued Products, H2 2014 51
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
